Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289546 | 0.91 | ESR2 (1.00) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8288583 | 0.88 | ESR2 (1.00) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11369250 | 0.81 | ALDH1A1 (0.97) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3914067 | 0.80 | ALDH1A1 (0.84) | ESR2SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6248815 | 0.80 | MEN1 (0.81) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3278398 | 0.79 | ALDH1A1 (1.00) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5806397 | 0.79 | ALDH1A1 (0.74) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6246144 | 0.79 | MEN1 (0.83) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5806395 | 0.79 | ALDH1A1 (0.74) | ESR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8289734 | 0.78 | ALDH1A1 (0.76) | ESR2POLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | ESR2 4200/4885POLB 831/4885SMN1; SMN2 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.